Sol-Gel TechnologiesSLGL
Recorded

Sol-Gel Technologies Investor Day 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration2 hr 4 minParticipants10

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Mori ArkinCEO

So, good morning. Actually, good afternoon to our guests that took the trouble to visit us here, and to everyone that is listening to us, and the Sol-Gel team that are also watching us in Israel and is our biggest support along this journey. First of all, I would like to thank our great guests, the scientists who agreed to speak to you. They will be introduced later, one after the other. And we, the team of Sol-Gel and the management team that is here, are very excited to talk to you about the prospects that we see in revolutionizing the treatment of Gorlin, and introducing such a profound change in the life of Gorlin patients with our new drug, SGT-610. So, thank you again. I will now start our presentation.

Mori ArkinCEO

Many of our investors are familiar with the presentation because it was in our company deck, but we introduced several changes that were meant to respond to frequently asked questions by you guys over the last month or two. And I hope this presentation will add clarity in those aspects that were maybe not fully clarified until now. So to introduce ourselves. Sorry. Introduce ourselves. Sol-Gel is an experienced dermatological company, specializes in severe, or if you will, rare diseases in dermatology. SGT-610 being the first product that is now approaching approval. This is our team. You see the team, all very serious-looking people. And one thing that makes me feel a bit apologetic is that we have only one lady here. And in fact, when I stepped up as the CEO last year, I was concerned about it, and I was asking myself how can I make a change?

Mori ArkinCEO

But all these people are so talented, so experienced, so diligent. There was no one I could replace. So what slightly corrects the situation is that our VP of Clinical and Regulatory Affairs, Dr. Ofra Levy-Hacham, has two jobs, both of regulatory and clinical. And in reality, I can tell you, she does a job of two executives. Hi, Ofra. And this slightly corrects the imbalance. But we are fully aware that a right company these days should consist of more balanced gender. Okay, now again. So just in highlights, what we are going to talk about. Our drug is, of course, first and foremost, is targeted at Gorlin patients. I'm saying first and foremost because in the future, I believe there will be additional indications, maybe even bigger than that, but right now we concentrate on Gorlin patients. The mechanism is a well-known mechanism.

Mori ArkinCEO

It's the blocking of the Hedgehog signaling pathway. And the development history, as we know, is that we acquired the drug from PellePharm. PellePharm did not fail in the study or did not meet the statistical significance that they expected. We've made a lot of due diligence, employed several independent statistical teams as well as world experts, and decided that the data that we will review later is really compelling, and we are biased as we are. We are quite convinced that this drug will be a success. In terms of the designation, it's an orphan drug and a breakthrough, and will be the first drug to treat Gorlin patients after so many years. So we are very excited about this. Now let us start with the data. This is the raw data of PellePharm phase III with one addition, is that we are showing here only the observed data.

Mori ArkinCEO

Only patient that completed 12 months treatment. This was not the data that was submitted to the FDA, but it is the data after we eliminated those people, patients that did not comply, that did not show up, that do not have the final data. I am making note of it because this was the source of some questions that we have been asked about the past. The PellePharm data shows this one, and you show that one. This is the data that our experts has done, our statistical team, based on the raw data of PellePharm. What did we learn from the PellePharm study? What observations led us to believe that this is going to be a great drug? Here is the first graph. It is a post hoc analysis and show that patients who do not have the PTCH1 mutation do not respond any better than a placebo.

Mori ArkinCEO

This is very surprising observation. Although it makes sense, it is still surprising because other studies made on Hedgehog inhibitors did not make this distinction. We know that it is valid for our drug, and we suspect that it is valid for other topical Hedgehog inhibitors if in the future someone will think about developing. This is very, very important and makes much of the change in our study. Patients without mutation has a very same response as placebo. Let us go further. I am accustomed that someone else does this job for me, so I apologize. Here, this is one of the changes that introduced, in order to overcome this block of 10 BCCs that people feel that this was somehow just a drug for people with 10 BCCs and more. Here is the data and please listen to the definition.

Mori ArkinCEO

In the post hoc analysis, a greater number of BCCs at baseline was associated with larger treatment effect favoring patidegib over vehicle. Large treatment effect means the separation between the drug and placebo. What you can see here is two things. First of all, patients that have less than 10 onwards, eight onward, six and up, had the very same efficacy as those of 10 and onwards, the same efficacy. Had we used a larger patient selection, namely from six BCCs onward, we would have reached the same p-value, more or less. 10 was used for some reasons, maybe for statistical considerations, to increase the likelihood of success in the study. But the drug's efficacy is equal for two BCCs, for three BCC, for five and with 10. The efficacy is equal because the mode of action is equal. We just inhibit the Hedgehog system.

Mori ArkinCEO

We inhibit the transcription factors downside to PTCH, and the proof is the reduction of the levels of Gli in the tumor. The drug does not know if it is two or 10. It is the same efficacy. What is different is the response of the placebo patients. What we have realized is that while the drug is always the same, patients with a mild, stable disease do not grow new BCCs, and therefore it is impossible for the drug to overcome the placebo and to show its advantage, because the drug is supposed to prevent BCCs to grow. If the BCCs do not grow in the first place, there is no way for us to show the advantage of the drug.

Mori ArkinCEO

Again, I would like to hammer this because all baseline BCCs respond to the drug, but the difference is dramatic in placebos. The placebo of low BCC number, they simply didn't grow in this particular study, not in real life. In real life, patients with one or two or three can suddenly experience a breakout of BCCs. But in this study, these were mild patients with stable disease, and therefore we were not able to see in that small group of patients the advantage of the drug. Let's go further. Now on the right is the graph that convinced our management to do the deal with patidegib and for me and my family to invest a significant bit of additional amount in order to support the study. Everything is in this graph.

Mori ArkinCEO

You see despite the small number of patients that qualify, despite the high standard deviation, despite all this, we show a dramatic difference between the drug and the vehicle, and a statistically significant one. What I would also suggest to take note of is that you see that the graph of the drug is almost leveling off. If we continue this graph for another 3 months or 6 months, it probably will be level off at about 3 because it's already asymptotic, as the technical word is. But here, the slope is growing. In all likelihood, 3 months from now, it would have been 8 against 3. So the protective effect will be 5 BCCs. It means 5 more surgeries spared.

Mori ArkinCEO

This is a very powerful demonstration of how effective is the drug, and it also, you may recall, we may go back to this slide when we talk again about the patient selection. You see that one year is not enough to capture the full protective effect of this drug. That is the biological process. A good company when planning a study, and that is something that the FDA has also suggested, we'll come to it in a moment, has to find the ways, have to find the selections that will be able to reveal the potential of the drug within the limitation of number of patients, the severe disease, and with the limitation of time. In one year, we have to show as much as possible.

Mori ArkinCEO

If we take patients that maybe will take them 2 years to respond because they have a stable disease, these patients are not suitable for that studies. This is the reason that convinced us to go on with the product. Let's go. Sorry again. Now, this is something interesting that maybe will give some color to the interaction with the FDA and as a background to our confidence that the FDA will be forthcoming and agrees to our thinking. It's so important I will read it with your permission. "We recommend," says the FDA, "conducting a new adequately powered randomized vehicle control trial to support the efficacy of your product.

Mori ArkinCEO

However, it may be possible to identify study design elements from the completed trial that could be modified in the future trial to increase the power, such as identify more sensitive patients population among Gorlin patients or including a broader population such as subjects with non-Gorlin high-frequency BCC. What you see here, what we did is precisely what the FDA recommended. We started a new study with what we believe is the more sensitive patients, the patients that are likely to respond to the drug. Again, I wouldn't say that we are aligned with the FDA because FDA can do whatever they choose, right? But certainly it is something that is in the spirit of the recommendation of the FDA. So this is a summary again of all the improvements that we introduced in the studies. Two of them refer to patient selections.

Mori ArkinCEO

We use facial BCC 3 and above. It was the previous study, and our study was 10 and above. PTCH mutation was not mandatory in the PellePharm study, and it is mandatory in our study, and that's it. In terms of operational improvement, we introduced several important changes that we think will improve the accuracy of the study, reduce false positive or false negative, and as we already know, has also reduced the number of dropouts patients. As a result, every patient that drops out costs dearly to the statisticians. So the fact that we have only 10% dropout is the result of some of our measures taken.

Mori ArkinCEO

First of all, because we're talking about Gorlin patients with many small red dots that may be diagnosed either as BCC or as rosacea or something, it was very important to use dermatoscope, here it's called dermoscope, in order to make the right differentiations. We know for a fact that it works because in the previous studies, we experienced a lot of what we nickname as zigzag effects, namely high number of visit seal, then the second visit low, and then high again. This doesn't happen in this study, so we made it mandatory to use a dermatoscope. We introduced a very qualified and central photography review board, namely every diagnosis is then revised by the specialists for the review board. If there is disagreement, they negotiate the primary investigator and the KOL from the review board until they come to the agreement.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day